Our data further indicate that blocking the LIF/LIFR signaling pathway could decrease cancer stemness in breast cancer cells, which points to a potential clinical application of targeted therapy using a LIFR inhibitor for breast cancer cells. This evidence concerns the gene LIFR and breast carcinoma.